1. Medtech Insight
  2. >>Business
  3. >>Deals

Minute Insight: ResMed to Buy German Software Company For $1B To Expand Outside US

 
• By Marion Webb

ResMed’s planned buy-out of Germany health care software company Medifox is expected to strengthen its position with out-of-hospital providers outside of the US and strengthen its position as a worldwide leader in health care software solutions.

Minute Insight
• Source: Informa/Alamy

ResMed, Inc. announced on 14 June it will acquire Medifox Dan, a German software company that provides out-of-hospital software solutions, which will expand ResMed’s portfolio into new health care sectors including outpatient therapy.

Medifox Dan’s software supports administration, billing, and other services and complements the solutions offered by ResMed’s US businesses MatrixCare and...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Medtech Insight for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Deals

More from Business

Daye Breaks Into Hormone Self-Testing, Adds New Data To Extensive Gynecology Database

 
• By Natasha Barrow

Daye is launching an at-home reproductive hormone testing service in the UK, utilizing a painless upper arm blood collection method. The product’s UKAS lab accreditation helps build credibility with healthcare providers.

BD Sees $90M Tariff Hit In Q4; 2026 Impact Reduced To $275M

 
• By Shubham Singh

BD raised its adjusted earnings per share guidance midpoint by $0.18 to a range of $14.30 to $14.45, representing growth of about 9.4% at the midpoint – an increase of approximately 1.4% over prior guidance.

Roche Eyes 2026 FDA Nod After CE Mark For pTau181 Test To Boost Global Alzheimer’s Diagnosis

 
• By Shubham Singh

The Elecsys pTau181 test, which requires only a blood sample, provides a less invasive alternative to cerebral spinal fluid procedures. A negative result could rule out Alzheimer’s and help patients avoid further testing with CSF or PET scans.